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Abstract. 1 
Background. Functional variants of  inosine triphosphatase (ITPA) were recently found to 2 
protect against ribavirin (RBV)-induced hemolytic anemia. However, no definitive data are yet 3 
available on the role of plasma RBV concentrations on Hb decrement. Moreover, no data have 4 
been published on the possible interplay between these two factors. 5 
Methods. A retrospective analysis included 167 patients. The ITPA variants rs7270101 and 6 
rs1127354 were genotyped and tested using the χ2-test for association with hemoglobin (Hb) 7 
reduction at week 4.  We also investigated, using multivariate logistic regression, the impact of 8 
RBV plasma exposure on Hb concentrations.  9 
Results. Both SNPs were associated with Hb decrease. The carrier of at least one variant allele in 10 
the functional ITPA SNPs was associated with a lower decrement of Hb (-1.1 g/dL), as 11 
compared to patients without a variant allele (-2.75 g/dL; p=4.09x10
-8
). RBV concentrations 12 
were not influenced by ITPA genotypes. A cut-off of 2.3 μg/mL of RBV was found to be 13 
associated with anemia (Area-Under-ROC=0.630, sensitivity=50.0% and specificity=69.5%, 14 
p=0.008). In multivariate logistic regression analyses the carrier of a variant allele (p=0.005) and 15 
plasma RBV concentrations below 2.3 μg/mL (p=0.016) were independently associated with 16 
protection against clinically significant anemia at week 4. 17 
Conclusions. Although no direct relationship was found between ITPA polymorphisms and 18 
plasma RBV concentrations, both factors were shown to be significantly associated with anemia. 19 
A multivariate regression model based on ITPA genetic polymorphisms and RBV trough 20 
concentration was developed for predicting the risk of anemia. By relying upon these two 21 
variables, an individualized management of anemia seems to be feasible in recipients of 22 
PEG/IFN-RBV therapy.  23 
INTRODUCTION.  1 
Hepatitis C virus (HCV) is one of the major causes of liver cirrhosis and hepatocellular 2 
carcinoma 
1
. Sustained viral response (SVR), defined as undetectable plasma HCV RNA 24 3 
weeks after the end of treatment, is achieved in less than 50% of patients with genotype-1 4 
infection using the currently recommended regimen consisting of pegylated-interferon 5 
(PEG/IFN) and ribavirin 
2
. 6 
Anemia is a major untoward effect of anti-HCV chronic therapy. Both PEG/IFN and ribavirin 7 
(RBV) play a role in haemoglobin (Hb) decrease, although most of the responsibility is by far 8 
attributable to the latter. Moreover, with the forthcoming introduction of the new HCV protease 9 
inhibitors, telaprevir and boceprevir, the incidence of anemia is likely to increase, as shown by 10 
the results of recent clinical trials 
3-5
. 11 
Repeatedly, individual RBV dose and pharmacokinetic (Pk) exposure  have been found to be 12 
consistent determinants of treatment-associated anemia, and recommendations on dose reduction 13 
have been released in order to mitigate thw impact of RBV on the severity of anemia 
6-10
.  Some 14 
other studies have not observed an association between hemoglobin decline and plasma RBV 15 
concentrations, when multivariate analyses were performed 
11-13
. 16 
 17 
Among the non-modifiable individual factors also contributing to anemia development in 18 
recipients of anti-HCV therapy, single nucleotide polymorphisms (SNPs) in the human DNA 19 
region coding for inosine triphosphatase (ITPA) were identified recently as the most significant 20 
variables influencing the risk of anemia. In these studies, by using a genome-wide association 21 
approach, two functional variants of ITPA, including one coding and one intronic variant, were 22 
found to be associated with treatment-induced anemia in HCV-infected patients 
5, 14, 15
, as 23 
defined by the magnitude of Hb reduction after 4 weeks of treatment.  This genetically 1 
determined vulnerability was subsequently confirmed in several ethnically heterogeneous 2 
clinical cohorts. The association signal was accounted for by 2 functional variants in the ITPA 3 
gene on chromosome 20: a missense variant in exon 2 (rs1127354, P32T) and a splice-altering 4 
single nucleotide polymorphism in intron 2 (rs7270101). Both polymorphisms had previously 5 
been well characterized and validated as functional variants in studies of patients with ITPase 6 
deficiency, a benign inherited enzymopathy in which inosine triphosphate (the substrate for 7 
ITPase) accumulates in red blood cells 
16, 17
. 8 
A recent study established that intraerythrocytic accumulation of ITP, as seen in carriers of such 9 
anemia-protecting mutants, provides an alternative source of nucleoside-triphosphates that 10 
eventually compensates for RBV-induced ATP reduction 
18
.  11 
Since it is not known whether any direct relationship exist between ITPA polymorphisms and 12 
RBV pharmacokinetics, the effects of ITPA genetic variants (rs7270101 and rs1127354) and 13 
RBV trough concentration on the development of ribavirin-associated anemia at week 4 were 14 
retrospectively evaluated in HCV-mono-infected patients who underwent PEG-IFN/RBV 15 
therapy, and had complete medical records as well as samples available for genetic and 16 
pharmacokinetic analyses. As a simultaneous evaluation of ITPA SNPs and plasma RBV 17 
concentrations for hemolytic anemia has not yet been published, we aimed to understand the 18 
contribution of each factor and any possible interplay between them. 19 
 20 
PATIENTS AND METHODS. 1 
Patients 2 
In this retrospective study, 234 patients with chronic HCV infection, treated in two university 3 
hospitals (Amedeo di Savoia and S. Giovanni Battista) of the city of Turin, Italy, between March 4 
2005 and November 2008 were enrolled.  5 
Patients were treated with PEG/IFN-α-2b (1.5 µg/kg s.c. once a week; sub dermal injection) or 6 
PEG/IFN-α-2a (180 µg once a week; sub dermal injection) plus RBV (600–1400 mg daily 7 
depending on bodyweight; orally). Sampling was performed after obtaining written informed 8 
consent in accordance with local ethics committee guidelines. Since patients’ authorization for 9 
routine sampling at the time of treatment did not include genetic analyses for polymorphisms 10 
(while therapeutic drug monitoring (TDM) of RBV is performed routinely and authorized on a 11 
regular basis since early 2005), patients were asked for an additional authorization for the genetic 12 
screening of their stored samples. Main inclusion criteria were: no concomitant interacting drugs, 13 
self-reported adherence > 95%, no RBV and/or PEG/IFN dose modification up to week 4 of 14 
treatment and no treatment with growth factor before week 4. Patients with other forms of liver 15 
disease, active hepatitis A, hepatitis B infection, HIV infection, decompensated liver disease, 16 
hepatocellular carcinoma, severe depression or other psychiatric diseases, significant cardiac or 17 
renal disease, seizure disorders or pregnancy were excluded from this study. Data collected 18 
included: age, gender, weight, previous IFN therapy, concomitant drugs, baseline and week 2 19 
and 4 biochemical parameters, such as white blood cells, Hb, alanine transaminase (ALT) level, 20 
serum HCV RNA level (logIU/mL). 21 
 22 
 23 
 1 
Genotyping 2 
Patients from whom DNA samples were available and who agreed to undergo genetic analyses 3 
were genotyped at polymorphic sites rs1127354, rs7270101 and rs6051702 on chromosome 20 4 
using the ABI TaqMan allelic discrimination kit by real time PCR using standard methodology. 5 
All primers, probes, and PCR conditions are available on request. The possible genotypes for 6 
each biallelic polymorphism are as follows: rs1127354: C/C, A/C, A/A (minor allele = A); 7 
rs7270101: A/A, A/C, C/C (minor allele = C); rs6051702: A/A, A/C, C/C (minor allele = C). 8 
 9 
Measurement of plasma ribavirin concentration 10 
At week 4, a time associated with the achievement of RBV steady-state 
19
, plasma samples were 11 
collected ~12 h after the dose administration of RBV, just before the following administration 12 
(trough value). Samples were centrifuged at 3000 rpm for 10 minutes to separate plasma and 13 
then stored at -80°C until analysis. Ribavirin concentrations were measured by a previously 14 
validated HPLC method 
20
. Briefly, the extraction of RBV from an aliquot of 250 µL of plasma 15 
was performed using 1500 µL of acetonitrile. The mixture was vortexed for 10 seconds and then 16 
centrifuged at 12,000×g for 10 minutes at 4°C and the supernatant was dried at 50°C. The dry 17 
extract was reconstituted with 125 μL of mobile phase then 30 μL was injected onto the column. 18 
Chromatographic separation was performed by an Atlantis 3μm dC18 column (150mm×4.6mm 19 
I.D, Waters, Milan, Italy), and RBV peak was detected at a wave length of 235 nm and retention 20 
time of 4.3 minutes. The calibration curve ranged from 0.078 to 10 μg/mL. Accuracy and 21 
precision standard errors were below 10%.  22 
 23 
 1 
Definition of Clinical End Points 2 
In common with most therapeutic studies on HCV chronic hepatitis treatment, Hb decline at 3 
week 4 was taken as the clinical endpoint and patients were classified according to two clinical 4 
cut-off: (a) absolute Hb value lower than 10 g/dL, and (b) Hb reduction >3 g/dL at week 4. 5 
 6 
Statistical Analysis 7 
For descriptive statistics, continuous variables were summarized as median (25th to 75th 8 
percentiles). Categorical variables were described as frequency and percentage. All data were 9 
assessed for normality using a Shapiro-Wilk test and categorical data were compared using a 10 
Mann Whitney or Kruskal-Wallis statistical test. To investigate continuous data, a Spearman 11 
Rank correlation was utilized. The association between individual ITPA SNP and the incidence 12 
of significant Hb decline was tested by a basic allelic test and calculated using the χ2-test. 13 
Receiver operating characteristic (ROC) curves were used to calculate cut-off values. 14 
Multivariate logistic regression analysis with stepwise forward selection was performed with P-15 
values of less than 0.05 as the criteria for model inclusion. Statistical analyses were conducted by 16 
using SPSS software package ver. 18.0 (Chicago, IL, USA) and using Prism 5.0 (GraphPad 17 
Software, San Diego, USA). Linkage disequilibrium analysis was conducted considering r
2
 and 18 
using Haploview 4.2.  19 
RESULTS. 1 
Sixty-seven out of 234 patients were excluded due to the lack of demographic and clinical 2 
information, including RBV plasma evaluation at week 4. 3 
Of the 167 patients included in the analysis, 90 patients (53.9%) were male, the median age was 4 
46 years (IQR, 38–58 years) and the median body weight was 69 kg (IQR, 62–75 kg). 161 5 
patients (96.4%) were Caucasian and 6 (3.6%) were African. 81 patients (48.5%) were treated 6 
with PEG/IFN-a-2a (180 µg/ once a week) and 86 (51.5%) were treated with PEG/IFN-a-2b (1.5 7 
µg/kg s.c. once a week). The median dose of RBV was 14.01 mg/kg (12.68-15.38). The majority 8 
of patients were treated with 800 mg (n=51) or 1000 mg (n=103) of RBV; three patients received 9 
600mg, nine 1200 mg and one 1400 mg.  10 
The median Hb reduction was -2.4 g/dL (-3.5 to -1.3) at week 4. 59 patients (35.3%) had anemia 11 
(Hb reduction>3g/dL or Hb<10g/dL) at week 4. Baseline Hb was correlated with Hb reduction 12 
(rho=-0.429 p=7.15x10
-9
).  13 
The variant allele frequencies for rs1127354 C/A, rs7270101 A/C and rs6051702 A/C were 14 
4.8%, 11.1%, and 13.7%, respectively. All SNPs were in Hardy-Weinburg equilibrium. The 15 
three SNPs in analysis did not result in Linkage Disequilibrium (r
2
<0.5) in our population. No 16 
differences concerning demographic, racial, physical characteristics and biochemical parameters, 17 
(Hb, platelet count, alanine transaminase -ALT- level, serum HCV RNA level) were observed 18 
among genetically defined groups.  19 
The two functional ITPA SNPs, responsible for inosine triphosphatase deficiency, (rs1127354 20 
and rs7270101) and the co-segregate SNP (rs6051702) were associated with the magnitude of 21 
hemoglobin decrease. Patients with rs1127354CC (n=151) had a larger hemoglobin decrement (-22 
2.5 g/dL, IQR -3.6 to -1.4), as compared to patients with CA/AA genotypes (-0.8 g/dL, IQR -1.1 23 
to -0.4, p=3.06x10
-6
). Similarly patients with genotype rs7270101AA (n=133) had a larger 1 
hemoglobin decrement (-2.5 g/dL, IQR -3.6 to -1.4), as compared to patients with AC/CC (-1.7 2 
g/dL, IQR -2.5 to -0.7, p = 0.002) and patients with rs6051702AA (n=129) had a larger 3 
hemoglobin decrement (-2.7 g/dL, IQR -3.7 to -1.7) as compared to patients with AC/CC (-1.1 4 
g/dL, IQR -1.9 to -0.7, p=3.4x10
-9
).  5 
Despite the strong association between the hemoglobin decrement and the polymorphism 6 
rs6051702, in the following statistical analysis we have  considered only the two functional 7 
polymorphisms of the gene ITPA, as described by other authors 
5, 21, 22
.  8 
As showed in Figure 1, the carrier of at least one variant allele in the functional ITPA SNPs was 9 
associated with a smaller decrement of Hb (p=4.09x10
-8
). In particular, patients with at least a 10 
variant allele in the functional ITPA SNPs (n=49) had a lower hemoglobin decrement (-1.1 g/dL, 11 
IQR -2.3 to -0.6), as compared to patients (n=118) without a variant allele (-2.75 g/dL, IQR -3.7 12 
to -1.7). No differences in Hb baseline between the wild type genotype patients and the carriers 13 
of a least one mutation for ITPA gene were observed (p=0.843). 14 
Median trough plasma RBV concentrations at week 4 were 2.1 μg/mL (1.63 to 2.68). Weight at 15 
baseline (rho=-0.286 p=4.0x10
-4
) and dose/kg of RBV (rho=0.265 p=0.001) were correlated with 16 
plasma RBV concentrations.  17 
RBV concentrations were not influenced by ITPA genotypes. Patients with rs1127354CC had a 18 
median RBV concentration of 2.1 μg/mL (1.63 to 2.68) compared with 1.76 μg/mL (1.50 to 2.6, 19 
p=0.269) in patients with the CA/AA genotype. Similarly patients with rs7270101AA had a 20 
median RBV concentration of 2.09 μg/mL (1.63 to 2.68) compared with 2.1 μg/mL (1.63 to 2.90, 21 
p=0.795) in patients with the rs7270101 AC/CC genotype. A trend towards higher RBV 22 
concentrations could be observed in patients with rs6051702AA with a median of 2.14 μg/mL 23 
(1.68 to 2.82), while patients characterized by rs6051702 AC/CC genotypes had median of 1.83 1 
μg/mL (1.47 to 2.20, p=0.067).  Plasma RBV concentrations at week 4 were correlated with Hb 2 
reduction at week 4 (rho=-0.183 p=0.025). 3 
To define the clinical relevance of genetic variants, trough concentration of RBV and other 4 
variables, we analyzed the proportion of patients with clinically significant anemia, which was 5 
defined as a decline of Hb more than 3 g/dL or an absolute Hb value lower than 10 g/dL. As 6 
summarized in Table 1, differences could be detected for baseline Hb, RBV trough 7 
concentrations and possession of variant alleles in the two SNPs. 8 
By using ROC curve analysis, a cut-off of plasma RBV concentration of 2.3 μg/mL was found to 9 
be associated with anemia (Area-Under-ROC=0.630, sensitivity=50.0% and specificity=69.5%, 10 
p=0.008). Using this cut-off, 30 out of 59 (50.8%) patients with a RBV concentration above 2.3 11 
μg/mL developed anemia, while this occurred in only 27/108 (25.0%) patients with RBV 12 
concentrations below 2.3 μg/mL (χ2=8.08, p=0.003).  13 
Many factors previously linked to anemia were also included in multivariate logistic regression 14 
analysis. As summarized in Table 2, carrier of variant allele (OR=0.29, p=0.005) and RBV 15 
plasma concentrations below 2.3 μg/mL (OR=0.42, p=0.016) were independently associated with 16 
protection against clinically significant anemia. The probability of developing anemia based on 17 
these two predictive factors is shown in Figure 2.  Considering patients with RBV concentrations 18 
below 2.3 μg/mL, the predicted probability of developing anemia was 35.5% for patients with 19 
wild type genotype for all SNPs (n=72) and 13.8% for patients with at least one SNP with a 20 
variant allele (n=31). Considering patients with RBV concentrations above 2.3 μg/mL, the 21 
predicted probability for patients with wild type genotype for all SNPs (n=47) was 56.8%, 22 
compared with 27.5% for patients with at least one SNP with variant allele (n=17). 23 
As shown in Figure 3 carriers of ITPA variants had a smaller decrease of Hb as compared to 1 
patients with wild type ITPA genotype. In the same figure and analysis it is also apparent that, 2 
regardless of the RBV concentration, in carriers of ITPA variants the magnitude of Hb 3 
decrement was found to have no significant association with plasma RBV concentration (rho=-4 
0.17, p=0.28), while the magnitude of Hb decrease among patients with the WT ITPA genotype 5 
had a strong and significant association with RBV concentrations (rho=-0.20, p=0.035).  6 
DISCUSSION. 1 
Recently several genetic variants associated with substantial effects on both efficacy and toxicity 2 
of PEG/IFN and ribavirin have been identified. SNPs in the IL28B gene were found to be 3 
strongly associated with response to therapy of chronic genotype 1 HCV infection 
23-27
, and 4 
SNPs in the ITPA gene were identified as predictors of RBV treatment-associated anemia in the 5 
European-American and Japanese populations 
5, 14, 15, 28
. The anemia experienced as a 6 
consequence of PEG/IFN and RBV combination therapy is primarily caused by a RBV-induced 7 
haemolysis and secondarily by interferon-induced bone marrow toxicity. Ribavirin toxicity can 8 
be explained by the accumulation of RBV phosphate metabolites in erythrocytes, oxidative 9 
damage and consequent cell lysis 
29
. The impact of anemia on the outcome of anti-HCV infection 10 
therapy is substantial, since RBV dose-reduction or early treatment interruption due to anemia 11 
often leads to suboptimal drug intake and a higher chance of treatment failure 
30
. The possibility 12 
of identifying those patients who are more likely to undergo significant Hb loss while on 13 
treatment might be  helpful in order to implement those measures which might limit the impact 14 
of anemia on treatment outcome.  15 
In this study the newly identified genetic polymorphisms of ITPA as well as RBV 16 
pharmacokinetic exposure, using RBV trough plasma concentration, confirmed their value as 17 
predictors of treatment-induced anemia, as established by HB reduction after 4 weeks of 18 
PEG/IFN-RBV treatment. Furthermore, we observed that baseline Hb was correlated with Hb 19 
reduction. However having a higher baseline HB concentration  is a biologically benign 20 
condition, which testifies to a higher functional reserve as compared to the other patients. For 21 
pure numerical reasons such condition is more vulnerable to a HB loss, since HB loss is here 22 
measured in terms of absolute values rather than percentage HB loss from baseline. 23 
Although, in addition to ITPA polymorphisms and RBV concentration, a series of individual 1 
features such as age, platelet count, haemoglobin concentration and haptoglobin phenotype were 2 
found to have some degree of association with the risk of anemia 
8, 31, 32
, the only modifiable 3 
factor of these variables is RBV pharmacokinetic exposure, which shows remarkable variability 4 
among HCV-infected patients 
33
. Thus, the early assessment of RBV concentration is suggested 5 
by some studies 
34, 35
 in order to adjust individual RBV dose.  6 
Following the identification of ITPA polymorphism as the strongest predictor of anemia in 7 
PEG/IFN-RBV recipients, the question arises as to how to integrate this newly identified genetic 8 
marker with RBV trough concentration in order to predict and manage the individual risk of 9 
anemia. According to our results, there is no apparent correlation between ITPA polymorphisms 10 
and RBV pharmacokinetic exposure, as also expected by the reported lack of association 11 
between ITPA polymorphism and treatment outcome.  12 
Thus, the two variables analyzed here, ITPA functional polymorphism and RBV concentration, 13 
retain their independent predictive values and display limited overlap in terms of predictive 14 
value. As shown in figure 2, the reciprocal increase in predictive value provided by either 15 
variable is significant. When relying upon RBV exposure, it is apparent that with high RBV 16 
concentration the possession of ITPA variants is associated with a lower risk of anemia as 17 
compared to patients with WT genotype and, changing the point of view, patients with the same 18 
ITPA genetic profile have a higher risk of anemia in case of higher RBV concentration. 19 
Thus, the introduction of the described ITPA genetic polymorphism substantially improves our 20 
ability to predict the individual risk of treatment-induced anemia (perhaps also considering the 21 
non-functional polymorphism rs6051702?). The main implication of our results is that the 22 
possession  of ITPA variants is associated with a rather limited median Hb loss, independent of 23 
RBV concentration,  even when RBV concentration is above the threshold of 2.3 µg/mL. In our 1 
patients anemia occurred  in 8 of 49 ITPA variant carriers (16.3%) and in 51 of 118 of ITPA WT 2 
patients (43.2%). It is worth noting that the only 6 patients who had Hb value less than 10 g/dL 3 
at week 4 were all ITPA WT carriers.  4 
In practical terms, given that human genetic analysis is easier and quicker to perform, with 5 
turnaround time shorter than TDM of RBV, and that the technique is far more widespread than 6 
TDM, the baseline estimation of the individual risk of treatment-induced anemia seems now a 7 
step closer to becoming common practice. In this perspective, RBV TDM might maintain a role 8 
in the management of the prevailing proportion of patients with WT ITPA genotype, in whom 9 
RBV concentration may be fruitfully modified by RBV dose adjustment. Since RBV 10 
pharmacokinetic exposure is also associated with the rate of SVR 
6, 11, 13, 27, 36, 37
, the same might 11 
also apply to carriers of ITPA variants with suboptimal RBV concentration, in whom RBV dose 12 
may be increased with a smaller risk of anemia.  13 
In conclusion, this retrospective study confirms the high impact of ITPA SNPs on hemolytic 14 
anemia and seems to suggest a cut-off value for  trough plasma RBVconcentration. Although 15 
more studies are needed to  clarify and confirm the relationship between anemia, ITPA 16 
polymorphism and RBV pharmacokinetics, these results show that estimating the risk of anemia 17 
by relying upon both these two determinants was more accurate than the use of a single 18 
assessment of either variable, assuming  plasma RBV concentrations are a key factor to predict 19 
anemia. Moreover, these data might form the basis for the development of an individual 20 
screening algorithm able to reduce the impact of anemia on the rate of response to anti-HCV 21 
treatment.  22 
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Figure Legends. 1 
Figure 1. The possession of at least one variant allele in the functional ITPA SNPs (n=49) was 2 
associated with a smaller decrement of Hb (g/dL) at week 4 (p=4.09x10
-8
). Median values 3 
(horizontal line), IQR (bars), patient values (black square), highest and lowest value (whiskers) 4 
are shown. 5 
 6 
7 
  
 1 
Figure 2. The predicted probability of developing anemia considering the possession of variant 2 
alleles and RBV concentrations (cut-off of 2.3 μg/mL) in multivariate logistic regression. The 3 
predicted probability of anemia is 13.8% for Yes-Carrier and Yes-RBV<2.3, 27.5% for Yes-4 
Carrier and No-RBV<2.3, 35.5% for No-Carrier and Yes-RBV<2.3 and 56.8% for No-Carrier 5 
and No-RBV<2.3. 6 
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Figure 3. Scatter plot representing the correlation between RBV concentrations at week 4 2 
(μg/mL) and Hb reduction at week 4 (g/dL). Patient values (black dots for ITPA wild type and 3 
white square for ITPA variant carrier), linear regression (filled line for ITPA wild type and 4 
dotted line for ITPA variant carrier) are shown. Patients with the wild type ITPA genotype had a 5 
strong and significant association with RBV concentrations (rho=-0.20, p=0.035). 6 
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